Features
Latest Features Feature
Pharmaceutical companies are facing the prospect of sickly returns, increasing development costs and patent expiries. This has prompted them to turn to resources outside their own research and development capabilities, writes Nicola Boyes.
Electronic Networking: From Physician to Prescription
Hospital information systems can alleviate time, money and staffing pressures throughout the work chain.
Hospital information systems can alleviate time, money and staffing pressures throughout the work chain.
Consolidation May Immunise UK Biotech Investors
As share prices continue to tumble consolidation among stocks could be good news for investors.
As share prices continue to tumble consolidation among stocks could be good news for investors.
Drugmakers Braced for US Election Results
The forthcoming US Presidential elections could be set to cause massive changes for many industries.
The forthcoming US Presidential elections could be set to cause massive changes for many industries.
Pharming out a New Marketing Message
Marketing is becoming a bitter pill for pharma companies' advertising departments to swallow.
Marketing is becoming a bitter pill for pharma companies' advertising departments to swallow.
Diabetic Drug Delivery Opens Up
The global demand for innovative and better diabetes control continues to grow, as the number of sufferers increases.
The global demand for innovative and better diabetes control continues to grow, as the number of sufferers increases.
Waters' Back-Up Plan
What effect will Big Pharma mergers have on suppliers of pharmaceutical tools?
What effect will Big Pharma mergers have on suppliers of pharmaceutical tools?
Actelion Dismisses Big Pharma Threat
As Actelion holds its own, for once it is the big guys who are losing out.
As Actelion holds its own, for once it is the big guys who are losing out.
Gaining Microwave Speed
It takes 24 years from when a compound's potential is discovered until the publication of its clinical effectiveness.
It takes 24 years from when a compound's potential is discovered until the publication of its clinical effectiveness.
European Biotech's Funding Crisis
An unprecendented squeeze on EU biotechs is leading to a shortage of required capital.
An unprecendented squeeze on EU biotechs is leading to a shortage of required capital.
Japan's M&A Boom
Japan's acquisitions market has seen surprising growth in recent times, as generic drugs increase in popularity.
Japan's acquisitions market has seen surprising growth in recent times, as generic drugs increase in popularity.
Go Czech for Biotech
A skilled workforce and strong currency are two attractions backing the aim to turn Czech city Brno into a biotech hub.
A skilled workforce and strong currency are two attractions backing the aim to turn Czech city Brno into a biotech hub.
Pharma set for Costly Shopping Spree
As the big pharma players seek to ramp up their production, is M&A really worth the money?
As the big pharma players seek to ramp up their production, is M&A really worth the money?
Vytorin's Value to Improve
Despite concerns over its effectiveness and safety, the use of cholesterol-fighting drug Vytorin is set to increase.
Despite concerns over its effectiveness and safety, the use of cholesterol-fighting drug Vytorin is set to increase.
The Future for Biotesting
The pharmaceutical industry's annual CPhI exhibition is approaching, showcasing the latest innovation and development.
The pharmaceutical industry's annual CPhI exhibition is approaching, showcasing the latest innovation and development.
Roche May Clinch Genentech Before Key Avastin Results
Deena Beasley, Reuters, looks at Roche's bid for the remaining 44% of Genetech.
Deena Beasley, Reuters, looks at Roche's bid for the remaining 44% of Genetech.
For Bristol, a Steady Course May be Best Navigation
Lewis Krauskopf and Ransdell Pierson, Reuters, investigate the future for Bristol-Myers Squibb.
Lewis Krauskopf and Ransdell Pierson, Reuters, investigate the future for Bristol-Myers Squibb.
The Biotech Effect
Catherine Lafferty looks at the rising influence of biotech on the renewed focus of pharmaceutical manufacturing.
Catherine Lafferty looks at the rising influence of biotech on the renewed focus of pharmaceutical manufacturing.
Delay at the FDA
The US Food and Drug Administration has come under criticism recently for delays in approving new drugs for the market.
The US Food and Drug Administration has come under criticism recently for delays in approving new drugs for the market.
Cancer's Costly Controversy
Ben Hirschler of Reuters looks at how the rising price of cancer treatments is dissuading potential purchasers.
Ben Hirschler of Reuters looks at how the rising price of cancer treatments is dissuading potential purchasers.
Beating the Big C
The global market for cancer drugs is growing rapidly, but are we any closer to beating this often fatal disease?
The global market for cancer drugs is growing rapidly, but are we any closer to beating this often fatal disease?
Reality Bites: Disappointment in the R&D Sector
The pharmaceuticals industry is investing twice as much in R&D as it was a decade ago.
The pharmaceuticals industry is investing twice as much in R&D as it was a decade ago.
Amendments Set to Clear Ambiguity
The US government is imposing transparency rules on the relationship between physicians and pharmaceutical companies.
The US government is imposing transparency rules on the relationship between physicians and pharmaceutical companies.
Indian Takeover Targets
As the Indian drug market is set for major growth, foreign investors are finding the country's companies appealing.
As the Indian drug market is set for major growth, foreign investors are finding the country's companies appealing.
The Witty Answer to GSK's Future
Has Andrew Witty got what it takes to keep GlaxoSmithKline at the top? Nicola Boyes finds out.
Has Andrew Witty got what it takes to keep GlaxoSmithKline at the top? Nicola Boyes finds out.
Tracking the Drug Trail
Counterfeiting and fraud are significantly large risk factors when it comes to the safety of pharmaceutical products.
Counterfeiting and fraud are significantly large risk factors when it comes to the safety of pharmaceutical products.
